Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022-Reference-Cited by-同舟云学术

Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022

Published:2024-03-28 Issue:5 Volume:29 Page:559-563
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Kimura Shoji,Shigeta Keisuke,Tamura Shingo,Uchino Keita,Kimura Takahiro,Ozaki Yukinori,Nishio Hiroshi,Tsuchihashi Kenji,Ichihara Eiki,Endo Makoto,Yano Shingo,Maruyama Dai,Yoshinami Tetsuhiro,Susumu Nobuyuki,Takekuma Munetaka,Motohashi Takashi,Ito Mamoru,Baba Eishi,Ochi Nobuaki,Kubo Toshio,Kamiyama Yutaro,Nakao Shinji,Tamura Shinobu,Nishimoto Hitomi,Kato Yasuhisa,Sato Atsushi,Takano Toshimi,Miura Yuji^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10147-024-02501-7.pdf

Reference15 articles.

1. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512

2. Naito S, Tsukamoto T, Koga H et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol 38(5):365–372

3. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154. https://doi.org/10.1016/S0140-6736(10)61389-X

4. Nozawa M, Mukai H, Takahashi S et al (2015) Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol 20(5):1026–1034. https://doi.org/10.1007/s10147-015-0820-9

5. https://www.pmda.go.jp/files/000143619.pdf. Accessed 22 Nov 2023